Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative review examining the causes, burden and management of noninfectious conjunctival hyperemia (ocular redness). The review highlights the growing global prevalence of ocular redness driven by digital lifestyles, dry eye, contact lens wear, allergies an.

Business Wire • 12 hours ago

Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know

Bausch + Lomb (BLCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Feb 19, 2026

Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript

Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 18, 2026

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2025 financial results. “We didn't just grow in the fourth quarter – we grew smarter,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Meaningful EBITDA margin expansion and operating leverage is a clear sign of our commitment to financial excellence, and we plan to harnes.

Business Wire • Feb 18, 2026

Bausch + Lomb (BLCO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 18, 2026

Bausch + Lomb (BLCO) Lags Q4 Earnings Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.25 per share a year ago.

Zacks Investment Research • Feb 18, 2026

Ahead of Bausch + Lomb (BLCO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Bausch + Lomb (BLCO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.

Zacks Investment Research • Feb 16, 2026

BLCO or DHR: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical Services stocks have likely encountered both Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Feb 9, 2026

BLCO vs. HQY: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Bausch + Lomb (BLCO) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 23, 2026

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior t.

Business Wire • Jan 20, 2026